Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUAD SHOT Radiotherapy Combined With Pembrolizumab in Recurrent Head & Neck Cancer
NCT04373642Phase 2Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Dec 2020
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Oklahoma. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04373642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373642.